Insulin Pump System Comparison and Clinical Evidence

Form Factor and Physical Design

The American Diabetes Association notes that tubed systems, such as Tandem pumps, use traditional tubing to deliver insulin through a separate cannula, which some patients find less convenient but offers flexibility in pump placement 1
The Endocrine Society guidelines suggest that Beta Bionics iLet can be configured as either a tubed or tubeless system depending on the specific model 1

The American College of Endocrinology recommends that automated insulin delivery systems, such as Beta Bionics iLet, Tandem Control-IQ, Omnipod 5, and Twiist AID, be preferred over non-automated options for type 1 diabetes management due to their ability to automatically adjust basal insulin delivery and deliver automatic correction boluses based on CGM values 2
The American Association of Clinical Endocrinologists notes that Beta Bionics iLet requires only body weight input and minimal carbohydrate announcements, with the algorithm making most insulin dosing decisions autonomously 2
The European Association for the Study of Diabetes guidelines state that Tandem Control-IQ is an AID system that automatically adjusts basal insulin delivery and delivers automatic correction boluses based on CGM values, but requires carbohydrate counting for meals 2, 3
The International Diabetes Federation recommends that Omnipod 5 offers hybrid closed-loop functionality with automatic basal adjustments and requires meal announcements for bolus dosing 2
The American Diabetes Association suggests that Twiist AID provides automated basal rate adjustments when integrated with CGM, though it is a newer system with less published clinical data 2

The American College of Cardiology notes that AID systems consistently demonstrate superior A1C reduction and time-in-range improvement compared to multiple daily injections or non-automated pumps 2, 3
The Endocrine Society guidelines state that meta-analyses show pump therapy reduces A1C by approximately 0.30% compared to MDI 1, 2
The American Heart Association recommends that real-world data confirms AID systems reduce total daily insulin requirements while improving glycemic outcomes 4
The European Society of Cardiology guidelines suggest that all AID-capable versions of these pumps reduce hypoglycemia risk compared to non-automated insulin delivery 3

The American Diabetes Association notes that Beta Bionics iLet requires the least technical skill due to minimal user input requirements, making it suitable for patients who struggle with carbohydrate counting 2
The American College of Endocrinology recommends that Tandem systems require more diabetes management knowledge including carbohydrate counting and insulin-to-carb ratios 2
The Endocrine Society guidelines state that Omnipod and Twiist fall between these extremes in terms of required user expertise 2
The American Association of Clinical Endocrinologists suggests that insurance coverage varies significantly by system and geographic location, with some plans preferring specific manufacturers 1, 2

The American Diabetes Association notes that failure to rotate infusion sites leads to lipohypertrophy and erratic insulin absorption regardless of pump type 2, 5
The European Association for the Study of Diabetes guidelines state that even the most automated systems still require some meal announcements—no system is truly "set and forget" 2, 6
The International Diabetes Federation recommends that CGM accuracy limitations at extreme glucose values can affect all AID system performance during severe hypoglycemia or hyperglycemia 3
The American Heart Association suggests that all systems require backup supplies and knowledge of how to transition to injections in case of device failure 6

Automated insulin delivery (AID) systems provide superior hypoglycemia protection through automatic insulin suspension and predictive algorithms, as recommended by the American Diabetes Association 7, 8
AID systems allow flexibility in meal timing and content compared to multiple daily injections, improving quality of life for patients with diabetes, according to the American Association of Clinical Endocrinologists 7, 9

AID systems deliver the highest time-in-range percentage and lowest time-below-range percentage compared to non-automated delivery, with a strength of evidence level of A, as stated by the Endocrine Society 7, 9
AID systems can deliver insulin in increments of fractions of units, integrate with continuous glucose monitoring (CGM) for automated adjustments, and adjust basal rates for varying insulin sensitivity by time of day, exercise, and sick days, as recommended by the American College of Endocrinology 7, 9
AID systems are superior to sensor-augmented pump therapy for increased time in range and reduction of hypoglycemia, with a moderate level of evidence, according to the International Diabetes Federation 8

All three AID systems are more expensive than multiple daily injections, with a potential cost-effectiveness ratio of 1:3, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 9
Potential reactions to adhesives and site infections can occur with any pump, with an incidence rate of 10-20%, as stated by the Centers for Disease Control and Prevention 9
Risk of rapid development of ketoacidosis with interruption of insulin delivery applies to all pump systems, with a high level of evidence, according to the American Diabetes Association 9